18:27 , Oct 19, 2018 |  BC Week In Review  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
21:29 , Oct 17, 2018 |  BC Extra  |  Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
18:15 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting Chk1 alone or in combination with Gemzar gemcitabine could help treat STK11 -deficient NSCLC and other lung cancers. In three...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Checkpoint kinase 1 (Chk1; CHEK1)

Cancer INDICATION: Cancer Cell culture and mouse studies identified a pyrazine-2-carbonitrile-based Chk1 inhibitor that could help treat cancer. Chemical synthesis and in vitro testing of pyrazine-2-carbonitrile analogs identified a compound that inhibited Chk1 phosphorylation activity...
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Checkpoint kinase 1 (Chk1; CHEK1); MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2); K-Ras (KRAS); BRAF

Cancer INDICATION: Cancer Studies in patient samples and mice suggest combining inhibitors of Chk1 and MAPKAPK2 could help treat KRAS- or BRAF-mutant tumors. In tumor samples from patients with lung or colon adenocarcinomas, levels of...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

ARRY-575: Phase I started

Roche disclosed in its 2Q12 earnings that its Genentech unit began an open-label, international Phase I trial to evaluate multiple ascending-doses of oral GDC-0575 alone and in combination with gemcitabine in about 90 patients. Array...
07:00 , Aug 22, 2011 |  BioCentury  |  Strategy

Checkpoint match

With a pair of checkpoint kinase 1 inhibitors at similar stages of development, Genentech Inc. and Array BioPharma Inc. saw an opportunity for both companies to benefit by combining programs while ensuring neither has an...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Array BioPharma, Roche deal

Array partnered with Roche's Genentech Inc. unit to develop each company's oral checkpoint kinase 1 (Chk1) inhibitor for cancer. Genentech will be responsible for all clinical development and commercialization. The deal includes Genentech's GDC-0425 (...
07:00 , Aug 15, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) was off $1.48 (58%) to $1.06 on Wednesday after receiving a complete response letter from FDA for an NDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC)....